Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I double-blind, placebo-controlled, single ascending dose study for LX-9211 in healthy volunteers.

Trial Profile

A Phase I double-blind, placebo-controlled, single ascending dose study for LX-9211 in healthy volunteers.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 18 Dec 2018

At a glance

  • Drugs LX 9211 (Primary)
  • Indications Neuropathic pain
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Most Recent Events

    • 18 Dec 2018 Results published in the Media Release
    • 01 Nov 2018 According to a Lexicon Pharmaceuticals media release, data from this trial is expected in Q4 2018.
    • 22 Feb 2018 According to a Lexicon Pharmaceuticals media release, data from this trial is expected in 2H 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top